Vaccination Update By Japan and Irish

Japan begins administering fourth doses of the COVID-19 vaccine for medical staff and elderly care workers.
The Irish Ministry of Health announces changes to Ireland’s vaccination program including a second booster dose for people between the ages of 50 and 64 years and a first dose of an mRNA vaccine for children between the ages of 5 and 11 years who are immunocompromised.

Japan has so far approved Pfizer–BioNTech, Moderna and Oxford–AstraZeneca for use. In early October 2021, data from the government shows that 60.9% of people have had their second dose, while 71.3% have received first shot. In late October, they reached 70% population fully vaccinated. In Japan, the fourth dose was only available to people aged 60 and over and those between 18 and 59 with pre-existing conditions who are considered at higher risk when infected with the virus. The fourth vaccination is now available at three mass vaccination sites, including the Tokyo metropolitan government building, for residents of the capital or people who commute into the city. The nationwide daily case count exceeded 190,000 on Friday, marking a new record for the third consecutive day.

Ireland’s vaccination rollout has been praised as one of the most successful rollouts in the world and was ranked number one in the European Union in terms of its percentage of adult population fully vaccinated, and was also ranked number one in the EU for the number of booster vaccines administered. As of 21 July 2022, 11,003,334 vaccine doses have been administered, of which 4,092,885 people have received at least one dose, 3,804,600 have received their second dose and 3,105,849 have received a third or booster dose. The Minister for Health Stephen Donnelly has accepted new recommendations in relation to Ireland’s COVID-19 vaccination program. NIAC has recommended:

  • a first mRNA booster vaccine for those aged 5-11 years who are immunocompromised
  • a second mRNA booster vaccine for those aged 50-64 years
  • a second mRNA booster vaccine for those aged 12-49 years who have an underlying medical condition or are residents of long-term care facilities.
>